Translational Research in Pediatrics: Tissue Sampling and Biobanking abstract
Translational research is expanding and has become a focus of National Research funding agencies, touted as the primary avenue to improve health care practice. The use of human tissues for research on disease etiology is a pillar of translational research, particularly with innovations in research technologies to investigate the building blocks of disease. In pediatrics, translational research using human tissues has been hindered by the many practical and ethical considerations associated with tissue procurement from children and also by a limited population base for study, by the increasing complexities in conducting clinical research, and by a lack of dedicated child-health research funding. Given these obstacles, pediatric translational research can be enhanced by developing strategic and efficient biobanks that will provide scientists with quality tissue specimens to render accurate and reproducible research results. Indeed, tissue sampling and biobanking within pediatric academic settings has potential to impact child health by promoting bidirectional interaction between clinicians and scientists, helping to maximize research productivity, and providing a competitive edge for attracting and maintaining high-quality personnel. The authors of this review outline key issues and practical solutions to optimize pediatric tissue sampling and biobanking for translational research, activities that will ultimately reduce the burden of childhood disease. Pediatrics 2012;129: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Translational research is a process by which research results are made rapidly applicable to the population under study and is ideally bidirectional. [1] [2] [3] Knowledge from basic science is used to develop new diagnostics and therapies while clinical insights generate laboratory-testable hypotheses. 4 This directional balance creates an exciting and productive research environment, allowing for better understanding of disease states and fueling the common goal of better patient care. 5, 6 Patient tissue sampling and biobanking is a pillar of translational research, allowing for laboratory investigations on human disease. Tissue biobanking is challenging and requires established infrastructure, standardized protocols, and clinical databases. 1, 7 In pediatrics, tissue biobanking involves additional and unique barriers, 1 including small program sizes, fewer investigators, less subjects, unique ethical challenges, a large developmental spectrum, a preponderance of rare illnesses, difficulties in sample-collection methods, and small tissue-sample volumes. Despite these significant obstacles, pediatric biobanks are invaluable for providing scarce human material to meet the needs of child-health investigators for translational research.
In this review, the authors outline key issues and practical solutions for initiation or expansion of pediatric tissue biobanks. Further information on development of biobank networks and creation of standard operating procedures (SOPs) and best practices can be obtained from Web resources (Table 1) .
INTEGRATED SERVICES
The integrated services required for optimal tissue sampling and biobanking will depend on the tissue-collection model. Potential models include prospective collection, banking of pathologic specimens, or banking of specimens associated with clinical trials. 8, 9 Stored newborn-screening blood samples are also available but subject to research guidelines established by government agencies. [10] [11] [12] Prospective sample collection has proven successful for biorepository growth 8, 9 and relies on collection of tissues for prespecified research purposes, with unused portions retained for future research. The prospective model reduces costs of future research by eliminating the collection step, making more projects feasible, and providing for unexpected opportunities. 13 The scope of the specimens must be kept broad and the quality high to accommodate for shifts in research goals over time. 14 Research needs seem unchallenging on service initiation; however, once sampling frequency increases, it is often difficult to manage increasing demands. 8, 9 Regardless of the collection model chosen, integrated services should include bioethical support, consent and assent assistance, and collection of sample-matched clinical data. Services should follow SOPs (Table 2 ). To aid 
ETHICS AND INFORMED CONSENT
Tissue sampling and biobanking must be approved by the presiding institutional review board (IRB) or research ethics board (REB). Biorepository personnel should have ongoing communication with the IRB or REB, 15 and investigators must be familiar with local IRB and REB policies. Tissue specimens must be specified for valid biomedical research and not other purposes such as commercial gain, political reasons (eg, advancement of criminalinvestigation techniques and paternity tests or for immigration purposes), or for purely technical purposes. 16, 17 A biorepository committee comprising clinicians or scientists who are familiar with the needs of the translational research community should be formed to ensure the ethical and scientific validity of projects requiring samples. [18] [19] [20] Provision of bioethical support is critical toassist investigatorswith completionof ethics-review documents, including details of sample collection and processing, de-identification methods, storage, and off-site shipment. A potential approach to explore with the respective IRB or REB is for the biorepository to append its IRB/REB approval to individual investigators' protocols. Investigators also may require assistance with consent and assent once eligible participants or their legal guardians are identified and approached by their clinician. Involvement of experienced biorepository staff in the consent process is advantageous because it avoids potential conflicts of interest and the appearance of coercion by investigators. 15, 21 IRBs and REBs have differing views on participants giving broad consent for future use of their specimens in research. 16, 17, 22, 23 Consent for a single study jeopardizes the amount and quality of research that can be performed on a particular sample, 16 whereas broad consent allows multiple studies to use stored specimens. Most citizens are willing to give broad consent for research so long as the future use is approved by an IRB or REB. 16 Separate letters of information and consent for the biorepository and current investigation clarify to potential participants the intended use of their samples. Participants must be informed of potential genetic analyses on stored material and must be able to opt-out or be excluded from a study. DNA analysis can create special concerns, although this issue may be less germane for somatic mutations, such as those associated with cancer, rather than genetic mutations. 24, 25 Concerns include possible future genetic discrimination by employers or insurance companies. 25 Typically, there is increased scrutiny for projects involving children. 15, 21 Proxy consent must be obtained, and one must consider the involvement of the child in providing assent. 26 A complicating factor is the different age range considered appropriate for assent in different jurisdictions and special issues with respect to assent in adolescents. Emancipated or mature minors may be able to consent for themselves, depending on local laws. 27 IRBs and REBs may require assent from children .7 years of age 21 ; however, in 1 study it appeared that many children do not understand the concept of a biorepository. 26 Because the risk is minimal in most cases, assent may not be routinely necessary, although further investigation is required. Given enough information, parents or legal guardians should be able to make a proper assessment of benefits and risks for their children. [28] [29] [30] As a temporarily vulnerable population, children reserve the right to withdraw specimens from the tissue bank at any time after they reach the age of consent 16 ; however, requesting consent from adults for the ongoing use of their specimens collected in childhood is thought unrealistic. 31 The authors of 1 study concluded that children are generally trusting of their parents' decisions and have little concern over continued use of their specimens and data. 32 Parents should be advised to make information available to their children so that they can determine how they would like their samples to be used when they are adults.
When providing samples and matching clinical data to investigators, special care must be taken to maintain the privacy, confidentiality, and cultural sensitivities of children. 33 General findings from studies may be shared with families (including non-donors), and clinically relevant results may be shared with the participants, their physicians, and parents. 24, 25 Disclosure of information to parents may be considered a breach of autonomy because it prevents the child from exercising the right not to know, a choice a child might make as an adult. 25 Returning information from research analyses often is hindered by time lapse. 24 Deferred consent may be considered under special circumstances (eg, critically ill patients) and when collection times are crucial. If risk is minimal and the legally authorized representative is not present initially, the sample can be taken and informed consent can be obtained post-hoc (ie, within 24 hours). If consent is not subsequently obtained, the samples and data collected must be destroyed.
RESOURCES
Upfront costs for a biorepository include office and laboratory space, equipment, tissue-storage systems, a clinical database, and personnel. Ongoing costs include equipment maintenance and replacement, laboratory supplies, and operating expenses for which continued funding must be available. 9 
Infrastructure
The biorepository is located ideally within an academic hospital for patient access, clinical and research support, rapid collection and processing times, and elimination of tissue transfer offsite. The space must have level-2 biosafety approval, with directional airflow or use of a biological safety cabinet, and it must be accessible only to designated personnel. When studies involve samples from patients with potentially lethal infectious agents, level-3 approval is required. 34 Major equipment required at the outset includes a lockable, alarmed freezer (270°C or lower); a refrigerated centrifuge with sealed buckets; a refrigerator-freezer; and computer equipment. If the cross-contamination risk is low, the laboratory can share existing resources at the hospital or institution, including wet or dry ice, biological safety cabinets, and autoclaves. Other supplies are specific to the types of tissues being collected. 9, 35 With respect to cryogenic storage systems, smaller biorepositories may store samples in 0.5-to 2.0-mL cryovials with high-quality, laboratory printergenerated labels. For larger-scale biorepositories, two-dimensional barcode systems are available that can automate storage and retrieval, reduce human error, increase efficiency, and provide tubes and storage racks that are more space-saving. Software packages accompany these systems to document and verify storage information and hold sample data. Human-readable labels should be used on tubes because samples might become disorganized or transferred to laboratories without barcode scanners.
Personnel
A biorepository director familiar with both clinical and research aspects of translational research should be appointed. A major responsibility of the director is to foster communication and collaboration between laboratory scientists and clinicians. At the outset, the director contributes a considerable amount of his or her time to the facility. 9 An experienced research manager should be appointed to direct daily activities and should be familiar with human-tissue handling, biosafety, shipping regulations, and site-specific health andsafety issues.Theresearchmanager also might collect, process, and ship specimens; maintain the database; order supplies; update the budget; and revise the SOPs. Frequent interactions between the research manager and investigators optimize the research environment. If need or demand is sufficient, a pediatric-trained nurse or phlebotomist may be required.
Funding, Business Plan, and Cost Recovery
Ideally, biorepository services are not charged to local academic investigators, although additional funding often is required. 8 Funding sources include government-infrastructure granting agencies, academic or institutional core facility funds, or use of a foundation or charitable trust. 36 If funded by commercial partners, source publication renders potential conflicts of interest transparent. Public funding sources also should be reported, even if they arise from commercial parties. A business plan should be developed, identifying the goals of the center, its location and infrastructure, whom the center will be marketed to, services provided, personnel required, markers of success, and a 3-to 5-year budget.
Beyond initial start-up costs, many repositories fail to sustain ongoing funding. To prevent premature closure, it is important to campaign for institutional support from the beginning. 14 To demonstrate the value of the service, researchers who do not pay the actual costs of sample collection are invoiced, with the total billed shown as 0 so they will be aware of the actual costs of tissue procurement and storage and are more likely to be advocates for the biorepository. 14 Cost recovery may be targeted at industry-based trials and, if need be, academic researchers requesting stored biorepository samples. Multiple methods exist for determining fees (Table 3) . For large-scale repositories, cost per sample from the time of collection to shipping was estimated to be between US $60 and US $150. 37 In all cases, robust economic evaluations are encouraged to determine if key costs (eg, equipment maintenance and renewal) are included in the overall cost estimates.
SOPs
Standardized procedures for tissue collecting and biobanking are crucial for creating greater stability within and between samples and for preventing bias. Downstream applications should be considered when developing SOPs, and SOPs should be reviewed and updated regularly. SOPs also can be obtained through collaboration with preexisting biobanking facilities, biomarker networks, or trial groups (Table  1) , but adapted SOPs typically require alteration to reflect the challenges of pediatric biobanking. Pilot studies may be required to create SOPs when the research goals are specific. SOPs and best practices for biorepositories are outlined in Tables 2 and 4 . 8, [38] [39] [40] To maximize research productivity from limited tissue samples, 13 SOPs should be developed based on best practices and the needs of local investigators, while having a broad scope for sample viability in future research. In general, plasma is more biologically relevant than serum, because serum clotting can affect biomarker concentrations, 14, [41] [42] [43] [44] and it is imperative to minimize processing times and avoid freeze-thaw cycles.
TISSUE SAMPLES AND COLLECTION METHODS
Determination of the types of tissues to be collected (Table 4) establishes the services provided, the storage methods used, and the specific equipment and supplies needed. 8 For pediatrics, study design should include less invasive specimen types, including saliva, cord blood, and urine. 13, 33 Attempts should be made to collect research samples at the same time as those for clinical purposes, 27, 33 making it clear to potential participants that extra samples are being taken for research. In pediatrics, the vol or size of specimens is generally less than that obtained from adults, and often little specimen material remains for biobanking purposes.
Children participating in research should have specimens obtained in a friendly environment and by someone who is experienced in techniques applicable to children, 27,45 so the child does not become procedure-phobic. 46 Pediatric nurses or phlebotomists who are familiar with the coping mechanisms and distress signals of children are required. Bad experiences perceived by children result in greater distress with each visit, 46 making procedures difficult. 47 Indeed, some children will not consent to be in a research study because of fear of phlebotomy. 48 Research blood procurement should pose no increased risk for complications greater than that of standard Charge similarly to hospital laboratory Pricing from local hospital core laboratory Price reflects cost of processing only; Other sample costs underestimated; Quick and efficient way to get base prices Set cost similar to that of a research animal 8 Research prices of publically available animal models (murine) clinical venipuncture. Maximum daily and monthly amounts of blood that may be drawn from pediatric patients are listed in Table 5 . 33, 45 Vacuum bloodcollection tubes should be used only on older children because they can cause veins to collapse and stoppage of blood flow in young children. 46, 49 Butterfly needles are recommended for better control if the child moves during the procedure. 46 Using a syringe to collect blood, with alternating gentle suction-and-release method, will allow veins to refill 46 and also may prevent hemolysis. 8 Blood collection from ill pediatric patients raises concerns of inducing or aggravating anemia. 50, 51 Pediatric small-vol blood tubes (0.5-3.0 mL) should be used, and care should be taken to obtain suitable specimens the first time to minimize repeated sampling. Intravascular catheters should be considered if clinically indicated, and frequent sampling is required. 52 
CONTROL-SPECIMEN COLLECTION
Ideally, control-specimen collection is ongoing, because the availability of biorepository control specimens enables samples to be shared among researchers and reduces burden on volunteers. Identical SOPs should be used to collect control and study specimens, reducing bias (Table 2) , and any variables affecting sampling conditions must be documented. Splitting samples into both plasma and serum ensures availability for a wider number of research applications.
Lack of age-and gender-matched control specimens is a critical limitation for many pediatric studies. Generally, control specimens from healthy volunteers are collected from older children who are able to give assent; however, this practice poses a problem in matching samples to those from younger children with unique clinical variables. 41 An alternative option for younger children includes sample collection immediately after anesthesia induction for minor surgical procedures in otherwise healthy children.
Healthy volunteers may not always be the most suitable reference population. 41 Study-specific control samples matching the disease state and background of the patient may be more applicable. For example, a control sample to match with a patient on a ventilator with septic shock could be from someone free of infection who is also ventilated and receiving sedative medications. Drug-matched control specimens may be required when adverse drug effects are studied. In the research of rare, heritable diseases it is ideal to obtain samples from family members of those affected, and the biobank personnel can oversee simultaneous collection of these samples because parents often accompany their children.
CLINICAL DATA COLLECTION AND STORAGE
Clinical data linkage with tissue specimens is critical for personalized medicine. 53 To increase the biological value of each specimen, adequate clinical information should be obtained at the time of collection. 13, 14, 54 The patient data collected will vary according to the study, and common variables are summarized in Table 6 . At a minimum, the following preanalytical details should be collected: specimen type, SOP (and any deviations), collection date and time, sample vol (or mass for solid tissues), collection container, processing time, freezing time, and collection site. 8 Data storage can be accomplished with a pre-existing database [55] [56] [57] or by using commercial software that accompanies cryogenic storage systems. The database interface should allow for collection of equivalent information for each sample to reduce variability, and it should be user-friendly. 8 A vocabulary for the database should be created so that samples can be matched efficiently and reliably. Biorepository vocabulary is unique because there is generally different information needed to identify samples compared with clinical vocabulary. 8 Coding also may be used to describe preanalytical procedures and variables. 58 The database should be adaptable for incorporation of extra data, and it should track significant events such as sample thaws, loss, destruction, processing of any kind, and distribution. 39 When using a barcode system, the database must be capable of assigning a unique identifier (ID) to samples and tracking the other IDs required (specimen ID, subject ID, protocol ID, and so forth). Care must be taken not to overwrite or repeat IDs.
The database should be Web-accessed and password-protected so that information is remotely and safely accessible. Investigators are provided a unique access code, allowing them access to information particular to their project. The interface should be intuitive and generate reports summarizing data. All data available to investigators must be de-identified. To decrease the risk of patient identification, databases holding confidential patient information must meet the requirements of the Health Insurance Portability and Accountability Act 59 or equivalent. Generally, this requirement includes encryption, firewalls, unique access codes, and audit trails.
Sharing of tissue samples and clinical data has the possibility to increase research productivity, especially in the case of rare diseases. When biobanked samples and clinical data are shared, however, the donors have decreased control over their stored specimens and matched clinical information, including the inability to withdraw consent. 60 Local investigators should be consulted early to identify their research needs, and data-sharing policies should be described in the consent document.
CONCLUSIONS
Tissue sampling and biobanking is a pillar of translational research, but it is currently underutilized in child health research. A successful biorepository must be supported by a critical mass of investigators, have a significant infrastructure for continuous growth, and should adhere strictly to SOPs. Biorepository utilization can facilitate highquality translational research, decrease time to discovery, and ultimately, improve child health. 
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